2h
Hosted on MSNHUTCHMED Announces Major Equity Disposal in SHPLHUTCHMED (China) Limited has announced the disposal of a 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited (SHPL). The transaction involves selling 35% of SHPL to GP Health Service ...
We recently compiled a list of the 12 Best Small Cap Pharma Stocks to Buy Now. In this article, we are going to take a look ...
Liver cancer in the Philippines holds a staggering mortality rate of 11.6 out of 100,000 individuals, compared to the global death rate of 7.8/100,000. This reflects the significant impact of liver ...
HC Wainwright reiterated their buy rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a report ...
Stock analysts at Zacks Research reduced their Q3 2026 earnings per share estimates for shares of Gilead Sciences in a research report issued on Tuesday, February 25th. Zacks Research analyst E. Bagri ...
We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...
1. Characterization of lipid components in lipid nanoparticle (LNP) formulations – Application Note AN001928 – an-001928-bt-lipid-components-LNP-an001928-na-en.pdf (SECURED) ...
The Novato-based maker of biopharmaceutical treatments for rare diseases plans to release this year a new gene therapy for ...
This week's issue of Rubber News features our special report on the energy, oil and gas industries, including a deeper look ...
Is Viking Therapeutics, Inc. (VKTX) the Worst Performing Mid Cap Stock to Buy According to Analysts?
We recently published a list of 10 Worst Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are ...
(NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that SINOVAC has received on February 8, 2025 a formal court order (the “Order”) ...
Praxis Precision Medicines shares lost more than a third of their value on Friday after the clinical-stage biopharmaceutical company suffered a setback in its late-stage studies of its ulixacaltamide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results